Pazopanib Hydrochloride 200 mg Tablets

Pazopanib Hydrochloride 200 mg Tablets is a sophisticated, multi-targeted tyrosine kinase inhibitor (TKI) specifically engineered for the systemic management of advanced malignancies. As a powerful oral therapeutic, Pazopanib Hydrochloride 200 mg Tablets works by interfering with the signal transduction pathways that drive the growth and spread of cancer cells. Its primary mechanism of action involves the selective inhibition of various receptor tyrosine kinases (RTKs), most notably the vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and the stem cell factor receptor (c-KIT). By blocking these receptors, the medication effectively starves tumors of the blood supply they need to grow—a process known as anti-angiogenesis—while simultaneously inhibiting the proliferation of the tumor cells themselves. This dual-action approach makes Pazopanib Hydrochloride 200 mg Tablets an essential component in the oncological toolkit for patients battling progressive and metastatic diseases. Discover the ultimate benefits of this high-quality treatment designed to improve clinical outcomes and offer a path toward effective disease stabilization.

Indications / Uses of Pazopanib Hydrochloride 200 mg Tablets

Pazopanib Hydrochloride 200 mg Tablets is commonly prescribed for:

• Advanced Renal Cell Carcinoma (RCC): This medication is a first-line therapy for patients with advanced or metastatic renal cell carcinoma, a aggressive form of kidney cancer. By suppressing the vascular pathways that sustain kidney tumors, Pazopanib Hydrochloride 200 mg Tablets helps slow disease progression and can significantly extend progression-free survival in patients who have not responded to other therapies.
• Advanced Soft Tissue Sarcoma (STS): Pazopanib Hydrochloride 200 mg Tablets is indicated for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy. It is particularly effective for various subtypes of STS, helping to control tumor growth in tissues such as muscles, fat, and nerves where other treatments may have failed.
• Angiogenesis Inhibition: Beyond specific tumor types, the drug is used where potent inhibition of blood vessel formation within a tumor is required. This targeted pharmacological action prevents the “re-plumbing” of the tumor environment, making it harder for the malignancy to metastasize to distant organs.
• Maintenance Therapy: In certain clinical scenarios, Pazopanib Hydrochloride 200 mg Tablets may be used as a maintenance treatment to prevent the recurrence of tumors after primary surgical or radiological interventions have been completed.
• Dose Titration and Management: The 200 mg strength is frequently used to customize a patient’s daily regimen, especially when dose reductions are necessary due to side effect management, ensuring that therapeutic levels are maintained without compromising safety.

Key Features

• Targeted Precision Medicine: Unlike traditional chemotherapy that attacks all rapidly dividing cells, Pazopanib Hydrochloride 200 mg Tablets specifically targets the proteins on the surface of cancer cells and blood vessels, leading to a more focused therapeutic effect with a different side effect profile.
• Convenient Oral Dosing: The availability of this medication in tablet form allows patients to manage their treatment from the comfort of their home, avoiding the need for frequent clinic visits for intravenous infusions.
• Flexible Strength for Personalization: The 200 mg tablet size provides clinicians with the flexibility to fine-tune the dosage based on the patient’s specific tolerance and liver function tests, ensuring the most effective management of the condition.
• Proven Clinical Efficacy: Extensive clinical trials have demonstrated that patients using Pazopanib Hydrochloride 200 mg Tablets experience a significant delay in tumor growth compared to those on placebo or older treatment modalities.
• Multi-Pathway Blockade: By inhibiting three distinct families of growth factor receptors, the medication provides a comprehensive “multi-hit” strategy against the tumor’s survival mechanisms, reducing the likelihood of early drug resistance.

Storage for Pazopanib Hydrochloride 200 mg Tablets

To ensure the integrity and effectiveness of the medication, Pazopanib Hydrochloride 200 mg Tablets must be stored at controlled room temperature, ideally between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original manufacturer-provided bottle or blister pack to protect them from environmental factors such as excessive moisture and direct sunlight. Avoid storing this medication in humid environments like bathrooms or near kitchen appliances that generate heat. For safety, always keep the container tightly closed and store it in a high or locked cabinet to prevent accidental access by children or pets. If you have expired or unused medication, do not discard it in the household trash; instead, utilize a local drug take-back program or consult your pharmacist for safe disposal instructions.

Important Note on Pazopanib Hydrochloride 200 mg Tablets

The administration of Pazopanib Hydrochloride 200 mg Tablets requires strict adherence to specific protocols to maximize safety and efficacy. One of the most critical instructions is that this medication must be taken on an empty stomach—either at least one hour before a meal or two hours after a meal. Taking Pazopanib Hydrochloride 200 mg Tablets with food significantly increases the absorption of the drug, which can lead to dangerously high plasma concentrations and an increased risk of toxic side effects. Additionally, patients should avoid consuming grapefruit or grapefruit juice, as these can interfere with the metabolic enzymes (CYP3A4) responsible for breaking down the drug, potentially leading to toxic accumulation in the body.

Patients must be aware of the boxed warning regarding hepatotoxicity. Serious and sometimes fatal liver injury has occurred in patients taking this class of medication. Periodic liver function tests (ALT, AST, and bilirubin) are mandatory, usually before starting treatment and at regular intervals during the first few months. Another common side effect is hypertension; blood pressure should be well-controlled before starting therapy and monitored closely throughout. Other potential side effects include diarrhea, fatigue, hair color changes (depigmentation), nausea, and a decreased appetite. More serious risks involve QT prolongation (a heart rhythm issue), arterial thromboembolic events, and impaired wound healing. It is essential to inform your doctor about all other medications you are taking, including blood thinners, as Pazopanib Hydrochloride 200 mg Tablets can increase the risk of bleeding. If you experience severe abdominal pain, unusual bruising, or yellowing of the skin, seek medical attention immediately. Consistent communication with your oncology team is the key to a successful and safe treatment journey with this powerful medication.